West Pharm upgraded by Deutsche Bank with a new price target
$WST
Medical/Dental Instruments
Health Care
Deutsche Bank upgraded West Pharm from Hold to Buy and set a new price target of $250.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/14/2025 | $250.00 | Hold → Buy | Deutsche Bank |
| 1/8/2025 | $400.00 | Buy | Citigroup |
| 12/13/2024 | Peer Perform | Wolfe Research | |
| 12/12/2024 | $350.00 → $390.00 | Neutral → Buy | UBS |
| 2/7/2024 | $323.00 → $536.00 | Hold → Buy | Jefferies |
| 6/16/2023 | $390.00 → $405.00 | Neutral → Buy | BofA Securities |
| 4/11/2023 | $330.00 → $400.00 | Equal-Weight → Overweight | Stephens |
| 12/14/2022 | $250.00 | Hold | Deutsche Bank |
3/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
4/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
3 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., Feb. 13, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the fourth-quarter and full-year 2024 and introduced 2025 financial guidance. Fourth-Quarter Summary (comparisons to prior-year period) & Full-Year 2025 Guidance Fourth-quarter 2024 net sales of $748.8 million increased 2.3%; organic net sales grew 3.3%.Fourth-quarter 2024 reported-diluted EPS of $1.78 declined 2.7%; fourth-quarter 2024 adjusted-diluted EPS of $1.82 declined 0.5%.For Full-year 2025,
EXTON, Pa., Jan. 30, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 13, 2025, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast will be made available via the Company's Investor Relations website or by clicking here. To ask questions on the conference call, participant
EXTON, Pa., Jan. 28, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a first-quarter 2025 dividend of $0.21 per share. The dividend will be paid on February 11, 2025, to shareholders of record as of February 7, 2025. About West West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West
- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., Feb. 13, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the fourth-quarter and full-year 2024 and introduced 2025 financial guidance. Fourth-Quarter Summary (comparisons to prior-year period) & Full-Year 2025 Guidance Fourth-quarter 2024 net sales of $748.8 million increased 2.3%; organic net sales grew 3.3%.Fourth-quarter 2024 reported-diluted EPS of $1.78 declined 2.7%; fourth-quarter 2024 adjusted-diluted EPS of $1.82 declined 0.5%.For Full-year 2025,
EXTON, Pa., Jan. 30, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 13, 2025, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast will be made available via the Company's Investor Relations website or by clicking here. To ask questions on the conference call, participant
EXTON, Pa., Jan. 28, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a first-quarter 2025 dividend of $0.21 per share. The dividend will be paid on February 11, 2025, to shareholders of record as of February 7, 2025. About West West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
10-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal
EXTON, Pa., May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West's Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead our Global Operations and Global Supply Chain. The Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July 2022 to ensure a seamless transition.
Deutsche Bank upgraded West Pharm from Hold to Buy and set a new price target of $250.00
Citigroup initiated coverage of West Pharm with a rating of Buy and set a new price target of $400.00
Wolfe Research initiated coverage of West Pharm with a rating of Peer Perform